These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22227212)

  • 1. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound.
    McElroy WT; Tan Z; Basu K; Yang SW; Smotryski J; Ho GD; Tulshian D; Greenlee WJ; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1335-9. PubMed ID: 22227212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia.
    Ho GD; Yang SW; Smotryski J; Bercovici A; Nechuta T; Smith EM; McElroy W; Tan Z; Tulshian D; McKittrick B; Greenlee WJ; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1019-22. PubMed ID: 22222034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
    Gillespie P; Pietranico-Cole S; Myers M; Bilotta JA; Conde-Knape K; Fotouhi N; Goodnow RA; Guertin KR; Hamilton MM; Haynes NE; Liu B; Qi L; Ren Y; Scott NR; So SS; Spence C; Taub R; Thakkar K; Tilley JW; Zwingelstein C
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2707-11. PubMed ID: 24815509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.
    Rzasa RM; Frohn MJ; Andrews KL; Chmait S; Chen N; Clarine JG; Davis C; Eastwood HA; Horne DB; Hu E; Jones AD; Kaller MR; Kunz RK; Miller S; Monenschein H; Nguyen T; Pickrell AJ; Porter A; Reichelt A; Zhao X; Treanor JJS; Allen JR
    Bioorg Med Chem; 2014 Dec; 22(23):6570-6585. PubMed ID: 25456383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
    Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
    J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Acylhydrazones as inhibitors of PDE10A.
    Gage JL; Onrust R; Johnston D; Osnowski A; Macdonald W; Mitchell L; Urögdi L; Rohde A; Harbol K; Gragerov S; Dormán G; Wheeler T; Florio V; Cutshall NS
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4155-9. PubMed ID: 21696955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I.
    Das S; Harde RL; Shelke DE; Khairatkar-Joshi N; Bajpai M; Sapalya RS; Surve HV; Gudi GS; Pattem R; Behera DB; Jadhav SB; Thomas A
    Bioorg Med Chem Lett; 2014 May; 24(9):2073-8. PubMed ID: 24725435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and HMG CoA reductase inhibition of 4-thiophenyl quinolines as potential hypocholesterolemic agents.
    Cai Z; Zhou W; Sun L
    Bioorg Med Chem; 2007 Dec; 15(24):7809-29. PubMed ID: 17851082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of an irreversible HCV NS5B polymerase inhibitor.
    Zeng Q; Nair AG; Rosenblum SB; Huang HC; Lesburg CA; Jiang Y; Selyutin O; Chan TY; Bennett F; Chen KX; Venkatraman S; Sannigrahi M; Velazquez F; Duca JS; Gavalas S; Huang Y; Pu H; Wang L; Pinto P; Vibulbhan B; Agrawal S; Ferrari E; Jiang CK; Li C; Hesk D; Gesell J; Sorota S; Shih NY; Njoroge FG; Kozlowski JA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6585-7. PubMed ID: 24252545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors.
    Hu E; Kunz RK; Rumfelt S; Chen N; Bürli R; Li C; Andrews KL; Zhang J; Chmait S; Kogan J; Lindstrom M; Hitchcock SA; Treanor J
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2262-5. PubMed ID: 22365755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A.
    Plisson C; Salinas C; Weinzimmer D; Labaree D; Lin SF; Ding YS; Jakobsen S; Smith PW; Eiji K; Carson RE; Gunn RN; Rabiner EA
    Nucl Med Biol; 2011 Aug; 38(6):875-84. PubMed ID: 21843784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
    Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
    Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
    Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.
    Pannala M; Kher S; Wilson N; Gaudette J; Sircar I; Zhang SH; Bakhirev A; Yang G; Yuen P; Gorcsan F; Sakurai N; Barbosa M; Cheng JF
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5978-82. PubMed ID: 17827009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors.
    Rivkin A; Kim YR; Goulet MT; Bays N; Hill AD; Kariv I; Krauss S; Ginanni N; Strack PR; Kohl NE; Chung CC; Varnerin JP; Goudreau PN; Chang A; Tota MR; Munoz B
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4620-3. PubMed ID: 16784844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.
    Kravchenko DV; Kuzovkova YA; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Balakin KV; Ivachtchenko AV
    J Med Chem; 2005 Jun; 48(11):3680-3. PubMed ID: 15916416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.
    Rzasa RM; Hu E; Rumfelt S; Chen N; Andrews KL; Chmait S; Falsey JR; Zhong W; Jones AD; Porter A; Louie SW; Zhao X; Treanor JJ; Allen JR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7371-5. PubMed ID: 23149228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine.
    Wu Z; Yang C; Xiong Y; Feng Z; Lombardo M; Verras A; Chabin RM; Xu S; Tong X; Xie D; Lassman ME; Bhatt UR; Garcia-Calvo MM; Geissler W; Shen Z; Chen Q; Sinharoy R; Hale JJ; Tata JR; Pinto S; Shen DM; Colletti SL
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1774-8. PubMed ID: 22248857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinoline-4-methyl esters as human nonpancreatic secretory phospholipase A₂ inhibitors.
    Wu Y; Chen Z; Liu Y; Yu L; Zhou L; Yang S; Lai L
    Bioorg Med Chem; 2011 Jun; 19(11):3361-6. PubMed ID: 21555224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.